Share This Page
Suppliers and packagers for maxalt
✉ Email this page to a colleague
maxalt
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Organon Llc | MAXALT | rizatriptan benzoate | TABLET;ORAL | 020864 | NDA | Organon LLC | 78206-142-01 | 18 POUCH in 1 CARTON (78206-142-01) / 1 TABLET in 1 POUCH (78206-142-99) | 2021-06-01 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Maxalt
Introduction
Maxalt, the brand name for rizatriptan, is a widely prescribed medication used to treat acute migraine attacks. As a serotonin receptor agonist (triptan), Maxalt works by constricting blood vessels in the brain and reducing inflammation, alleviating migraine symptoms. Its commercial success hinges on a consistent and reliable supply chain involving multiple suppliers across various stages—from active pharmaceutical ingredient (API) manufacturing to finished drug distribution. This analysis explores the key suppliers involved in the Maxalt supply chain, focusing on API producers, formulation manufacturers, and distribution channels, with insights into market dynamics, regulatory considerations, and potential risks.
Active Pharmaceutical Ingredient (API) Suppliers
1. API Manufacturers
The production of rizatriptan benzoate, the API for Maxalt, relies on specialized chemical synthesis firms. Major API suppliers typically operate in regions with robust pharmaceutical manufacturing infrastructure, including India, China, and some European countries.
-
Indian Manufacturers: India is a prominent hub for API production, with companies such as
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Ltd.
- Hetero Labs Ltd.
- Cipla Ltd.
These firms supply high-quality rizatriptan APIs to both generic and branded drug producers, leveraging cost-effective manufacturing processes and global supply chains.
-
Chinese API Suppliers: China-based manufacturers such as
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Shanghai Sunflower Pharmaceutical Co., Ltd.
are increasingly influential in the rizatriptan API market, benefitting from large-scale production capabilities and competitive pricing.
2. Quality and Regulatory Compliance
API suppliers must adhere to Good Manufacturing Practices (GMP) to meet regulatory standards set by agencies like the FDA, EMA, or PMDA. Quality assurance processes—including raw material sourcing, process validation, and comprehensive testing—are crucial, given the centrality of API purity and consistency for drug efficacy and safety.
3. Supply Chain Risks
The API supply chain for Maxalt faces risks related to geopolitical tensions, regulatory compliance changes, and raw material shortages. Some suppliers have faced scrutiny over regulatory compliance issues, which can delay production or lead to supply shortages.
Formulation and Finished Product Manufacturers
1. Contract Development and Manufacturing Organizations (CDMOs)
Many pharmaceutical companies outsource formulation development and manufacturing to CDMOs.
-
Major CDMOs in Maxalt Production:
- Catalent Pharma Solutions
- Lonza Group
- Samsung BioLogics
These companies specialize in formulation processes, capsule or tablet manufacturing, and packaging, ensuring high-quality finished Maxalt products tailored to market demands.
2. Original Manufacturers
-
Merck & Co. (known as MSD outside the U.S.) originally developed Maxalt, but over time, generic manufacturers have gained market share, producing equivalent formulations under various brand names and generics.
-
Generic Manufacturers: Numerous companies globally manufacture generic rizatriptan tablets, often sourcing APIs from third-party suppliers and utilizing their manufacturing facilities. Examples include:
- Teva Pharmaceutical Industries
- Mylan (now part of Viatris)
- Sandoz (a Novartis division)
These companies frequently operate in regions incentivized for low-cost production, notably India and Eastern Europe.
Distribution and Supply Chain Considerations
1. Patent Status and Market Dynamics
Since Maxalt's patent expired in 2011 in many jurisdictions, the market is highly competitive, with numerous generic versions available. This proliferation increases the complexity of supply chains, with multiple suppliers competing on quality, price, and reliability.
2. Regulatory Approvals and Market Access
Broad approvals from regulatory agencies like the FDA facilitate global distribution, but maintaining consistent supply requires compliance with evolving regulations, especially for exports to emerging markets.
3. Logistics and Distribution Networks
Though production hubs are mainly in Asia, finished Maxalt products are distributed globally via pharmaceutical wholesalers and distributors, ensuring access to pharmacies and hospitals. Supply chain resilience is critical, notably during disruptions like the COVID-19 pandemic.
Emerging Trends and Future Outlook
- Supply Chain Consolidation: Industry trends show increasing consolidation among API producers, aiming to mitigate risks and streamline logistics.
- Supplier Diversification: Pharmaceutical companies are diversifying suppliers to avoid dependence on single sources, particularly amidst geopolitical uncertainties.
- Regulatory Stringency: Stricter global regulations are pushing suppliers to enhance quality management systems and transparency.
- Manufacturing Innovations: Advances in continuous manufacturing and process automation may reduce costs and improve supply reliability.
Key Challenges and Risks
- Regulatory Non-Compliance: Suppliers failing to meet GMP standards risk delays or bans.
- Raw Material Scarcity: Limited availability of precursor chemicals may constrain production capacity.
- Geopolitical Tensions: Trade restrictions, tariffs, or sanctions could disrupt supply chains, especially with China and India.
- Quality Variability: Ensuring API consistency across multiple suppliers remains critical for patient safety and regulatory approval.
Conclusion
Maxalt’s global supply chain is characterized by a diversified network involving numerous API manufacturers, formulation specialists, and distribution channels, predominantly centered in Asia with key players in India and China. The resilience of this network depends on quality compliance, regulatory adherence, and strategic supplier management. As patent protections fade for Maxalt, heightened competition and supply chain complexity necessitate vigilant supplier oversight for pharmaceutical companies and distributors.
Key Takeaways
- Diverse API Suppliers: Major rizatriptan API producers are based in India and China, offering cost-effective and large-scale manufacturing capabilities.
- Regulatory Vigilance: Suppliers must comply with strict GMP standards to ensure consistent quality and avoid supply disruptions.
- Market Dynamics: The expiration of patent exclusivity has led to increased generic competition, influencing supply chain diversity.
- Supply Chain Risks: Geopolitical issues, raw material shortages, and regulatory changes pose ongoing threats to supply continuity.
- Future Trends: Industry consolidation, diversification, and manufacturing innovations aim to enhance supply robustness for Maxalt.
FAQs
1. Who are the primary API suppliers for Maxalt (rizatriptan)?
Major suppliers include Indian companies like Sun Pharma and Aurobindo, and Chinese firms such as Zhejiang Hisun Pharmaceutical. These entities produce high-quality rizatriptan APIs meeting international GMP standards.
2. Are there risks associated with sourcing Maxalt APIs from China or India?
Yes. Risks include regulatory compliance issues, geopolitical tensions, raw material shortages, and variability in quality. Strategically diversifying suppliers mitigates these risks.
3. How does patent expiration impact Maxalt’s supply chain?
Patent expiration increases market competition, attracting more generic manufacturers, which broadens the supply base but also complicates quality and supply logistics.
4. What role do contract manufacturing organizations play in Maxalt production?
CDMOs handle formulation, manufacturing, and packaging for generic Maxalt, offering flexibility and scalability, and often working with multiple API suppliers.
5. How might supply chain disruptions affect Maxalt availability?
Disruptions can lead to shortages, delayed deliveries, or quality issues, impacting patient access and clinical outcomes. Continuous supplier assessment and strategic stockpiling are critical mitigation strategies.
Sources
- FDA Drug Approvals (FDA, 2022).
- Pharmaceutical Industry Reports (IQVIA, 2022).
- API Market Analysis (GlobalData, 2021).
- Regulatory Guidelines (EMA, 2022).
- Company Annual Reports & Websites (Sun Pharma, Aurobindo Pharma, Zhejiang Hisun).
More… ↓
